John E Anderson
Overview
Explore the profile of John E Anderson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1779
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miller E, Edelman S, Campos C, Anderson J, Parkin C, Polonsky W
Am J Manag Care
. 2024 Aug;
30(8):365-371.
PMID: 39146485
Objectives: To discuss the social, psychological, and access barriers that inhibit weight loss, and to propose steps and initiatives for addressing the growing obesity epidemic. Study Design: Narrative review of...
2.
Handelsman Y, Anderson J, Bakris G, Ballantyne C, Bhatt D, Bloomgarden Z, et al.
Metabolism
. 2024 Jun;
159:155931.
PMID: 38852020
The spectrum of cardiorenal and metabolic diseases comprises many disorders, including obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), dyslipidemias, hypertension, and...
3.
Butler J, Anderson J
JACC Heart Fail
. 2024 Jun;
12(6S):S7-S9.
PMID: 38839137
In this video, Javed Butler, MD, and John E. Anderson, MD, discuss the management of patients on SGLT2 inhibitors in the primary care setting.
4.
Butler J, Rich J, Pessah-Pollack R, Anderson J
JACC Heart Fail
. 2024 Jun;
12(6S):S10-S11.
PMID: 38839135
In this video, Javed Butler, MD, Jonathan Rich, MD, Rachel Pessah-Pollack, MD, and John E. Anderson, MD, summarize the key points of the enhanced publication "Role of SGLT2 Inhibitors in...
5.
Harris S, Mohammedi K, Bertolini M, Carlyle M, Walker V, Zhou F, et al.
Diabetes Obes Metab
. 2023 Sep;
25(12):3478-3489.
PMID: 37749746
Aim: Patient- and physician-associated barriers impact the effectiveness of basal insulin (BI) titration in the management of type 2 diabetes (T2D). We evaluated the experiences of patients with T2D and...
6.
Anderson J, Butler J, Alexandrov A
J Fam Pract
. 2023 Aug;
72(6 Suppl):S55-S60.
PMID: 37549420
Stroke is a significant cause of mortality worldwide, and diabetes is an independent risk factor for ischemic stroke occurrence and recurrence. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower the risk...
7.
Kushner P, Anderson J, Simon J, Boye K, Ranta K, Torcello-Gomez A, et al.
Clin Diabetes
. 2023 Apr;
41(2):258-272.
PMID: 37092144
This article reviews the efficacy and safety data of tirzepatide, a once-weekly, novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 (GLP-1) receptor agonist approved in the United States, the European...
8.
Harris S, Mohammedi K, Bertolini M, White J, Walker V, Zhou F, et al.
Diabetes Obes Metab
. 2023 Jan;
25(5):1408-1412.
PMID: 36633521
No abstract available.
9.
Aronne L, Anderson J, Sannino A, Chiquette E
Obes Sci Pract
. 2022 Jun;
8(3):363-370.
PMID: 35664250
Long-term therapeutic benefit of treatments for weight management in patients with overweight (also termed preobesity) or obesity may be limited by variable safety, tolerability, and efficacy profiles, and patient adherence...
10.
Handelsman Y, Anderson J, Bakris G, Ballantyne C, Beckman J, Bhatt D, et al.
J Diabetes Complications
. 2021 Dec;
36(2):108101.
PMID: 34922811
Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)-along with their associated risk factors-have overlapping etiologies, and two or more of these conditions...